WEST Search History

DATE: Friday, May 30, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L10	L8 and lda	0	L10
L9	L8 and lithiodiisopropylamine	0	L9
L8	L6 and glucose	83	L8
L7	L6 and uracil	1	L7
L6	L5 and (saccharid$5 or sugar or carbohydrate)	111	L6
L5	L4 and ceramide	120	L5
L4	L1 and (tumor or cancer)	1243	L4
L3	(((514/23 |514/25 |514/27)!.CCLS. |(536/1.11 |536/4.1)!.CCLS. |(544/1 |544/224 |544/242)!.CCLS.))	5494	L3
DB=USPT; PLUR=YES; OP=ADJ			
L2	L1 and (tumor or cancer)	1243	L2
L1	((514/23 |514/25 |514/27)!.CCLS. |(536/1.11 |536/4.1)!.CCLS. |(544/1 |544/224 |544/242)!.CCLS.)	4546	L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 18:11:11 ON 30 MAY 2003)

FILE 'REGISTRY' ENTERED AT 18:11:21 ON 30 MAY 2003

L1 STRUCTURE UPLOADED
L2 2 S L1 SSS SAM
L3 1213 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:12:26 ON 30 MAY 2003

FILE 'CAPLUS, USPATFULL, MEDLINE' ENTERED AT 18:12:40 ON 30 MAY 2003

L4 1158 S L3
L5 2 S L3 AND CERAMIDE
L6 105 S L3 AND (CANCER OR TUMOR)
L7 10 S L6 AND (SACCHARID? OR SUGAR OR CARBOHYDRATE)

L7 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:521462 CAPLUS
DOCUMENT NUMBER: 137:88442
TITLE: Incensole and furanogermacrens and compounds in treatment for inhibiting neoplastic lesions and microorganisms
INVENTOR(S): Shanahan-Pendergast, Elisabeth
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102
WO 2002053138	A3	20020919		

W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IE 2001-2 A 20010102
OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrens, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immundysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixt. showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

IT **1404-64-4**, Sparsomycin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 1404-64-4 CAPLUS
CN 2-Propenamide, N-[(1S)-1-(hydroxymethyl)-2-[(R)-[(methylthio)methyl]sulfinyl]ethyl]-3-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxo-5-pyrimidinyl)-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:78368 CAPLUS
DOCUMENT NUMBER: 134:131369
TITLE: process for the preparation of ceramide analogs and their use as antitumor agents

INVENTOR(S): Macchia, Bruno; Balsamo, Aldo; Macchia, Marco; Del Tacca, Mario; Danesi, Romano
PATENT ASSIGNEE(S): Bracco S.p.A., Italy
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007418	A2	20010201	WO 2000-EP7023	20000721
WO 2001007418	A3	20010510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1307786	B1	20011119	IT 1999-FI169	19990722
EP 1198458	A2	20020424	EP 2000-956250	20000721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505451	T2	20030212	JP 2001-512504	20000721

PRIORITY APPLN. INFO.: IT 1999-FI169 A 19990722
WO 2000-EP7023 W 20000721

OTHER SOURCE(S): MARPAT 134:131369
GI



I



II

AB The present invention discloses a process for the prepn. of ceramide analog (I; X1, X2 = O, S; R1, R2 = (CH2)13Me, (un)substituted alkyl, (un)substituted alkylene groups with one or more substituents selected among arom., primary, secondary and tertiary aminic, quaternary ammonium, CO2H, OH, polyoxyalkyl and ethereal groups, amino acids, halogen, **saccharidic** portions, providing that between R1 and R2 only one is (CH2)13Me; R3, R4 = H, (un)substituted alkyl, (un)substituted alkylene groups with one or more substituents selected among arom., primary, secondary and tertiary aminic, quaternary ammonium, CO2H, OH, polyoxyalkyl and ethereal groups, amino acids, halogen, **saccharidic** portion) and pharmaceutical formulations for the treatment of **tumors**. Thus, II was prepd. by the reaction of .beta.-ketoester III, Me(CH2)14CH(COCH2Me)COOCH2Me (obtained by the reaction of Et palmitate and propionyl chloride), with thiourea. II shows IC50 of 1.7 .mu.M in tests against human leukemia cell line called CCRF/CEM.

IT **322391-32-2P**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or

effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(process for the prepn. of ceramide analogs and their use as antitumor agents)

RN 322391-32-2 CAPLUS

CN 4(1H)-Pyrimidinone, 6-ethyl-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



IT **322391-31-1P 322391-33-3P 322391-34-4P**
322391-35-5P 322391-36-6P 322391-37-7P
322391-38-8P 322391-39-9P 322391-40-2P
322391-41-3P 322391-42-4P 322391-43-5P
322391-44-6P 322391-48-0P 322391-51-5P
322391-52-6P 322391-54-8P 322391-55-9P
322391-56-0P 322391-57-1P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the prepn. of ceramide analogs and their use as antitumor agents)

RN 322391-31-1 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-ethyl-6-tetradecyl- (9CI) (CA INDEX NAME)



RN 322391-33-3 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-ethyl-5-tetradecyl- (9CI) (CA INDEX NAME)



RN 322391-34-4 CAPLUS

CN 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-35-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-propyl-5-tetradecyl- (9CI) (CA INDEX NAME)



RN 322391-36-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-butyl-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-37-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-butyl-5-tetradecyl- (9CI) (CA INDEX NAME)



RN 322391-38-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2,3-dihydro-6-(2-methylpropyl)-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-39-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-(2-methylpropyl)-5-tetradecyl- (9CI) (CA INDEX NAME)



RN 322391-40-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(2,2-dimethylpropyl)-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-41-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-(2,2-dimethylpropyl)-5-tetradecyl- (9CI) (CA INDEX NAME)



RN 322391-42-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2,3-dihydro-6-(2-phenylethyl)-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-43-5 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-(2-phenylethyl)-5-tetradecyl- (9CI) (CA INDEX NAME)



RN 322391-44-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(3-aminopropyl)-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-48-0 CAPLUS
CN Glycine, 3-(1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-4-pyrimidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 322391-51-5 CAPLUS
CN L-Aspartic acid, 1-[3-(1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-4-pyrimidinyl)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322391-52-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2,3-dihydro-5-tetradecyl-2-thioxo-6-[3-[[3,4,6-tris-O-(phenylmethyl)-.beta.-D-glucopyranosyl]oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322391-54-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-[3-(.beta.-D-glucopyranosyloxy)propyl]-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322391-55-9 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(3-bromopropyl)-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-56-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2,3-dihydro-6-[3-(1-piperidinyl)propyl]-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-57-1 CAPLUS
CN 4-Pyrimidinepropanaminium, N,N,N-triethyl-1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-, bromide (9CI) (CA INDEX NAME)



● Br^-

IT **322391-45-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for the prepn. of ceramide analogs and their use as antitumor agents)
RN 322391-45-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-[3-[[(1,1-dimethylethyl)diphenylsilyl]oxy]propyl]-2,3-dihydro-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



IT **10606-53-8P 322391-46-8P 322391-47-9P**
322391-49-1P 322391-50-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the prepn. of ceramide analogs and their use as antitumor agents)
RN 10606-53-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 322391-46-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2,3-dihydro-6-(3-hydroxypropyl)-5-tetradecyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 322391-47-9 CAPLUS
CN Glycine, N-[(phenylmethoxy)carbonyl]-, 3-(1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-4-pyrimidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 322391-49-1 CAPLUS
CN L-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 4-(1,1-dimethylethyl) 1-[3-(1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-4-pyrimidinyl)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322391-50-4 CAPLUS
CN L-Aspartic acid, 4-(1,1-dimethylethyl) 1-[3-(1,2,3,6-tetrahydro-6-oxo-5-tetradecyl-2-thioxo-4-pyrimidinyl)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 10 USPATFULL

ACCESSION NUMBER: 2003:120833 USPATFULL

TITLE: HIV inhibiting pyrimidine derivatives

INVENTOR(S): Andries, Koenraad Jozef Lodewijk Marcel, Beerse, BELGIUM
De Corte, Bart, Southampton, PA, UNITED STATES
De Jonge, Marc Rene, Tilburg, NETHERLANDS
Heeres, Jan, Vosselaar, BELGIUM
Ho, Chih Yung, Lansdale, PA, UNITED STATES
Janssen, Marcel August Constant, Vosselaar, BELGIUM
Janssen, Paul Adriaan Jan, Vosselaar, BELGIUM
Koymans, Lucien Maria Henricus, Turnhout, BELGIUM
Kukla, Michael Joseph, Maple Glen, PA, UNITED STATES
Ludovici, Donald William, Quakertown, PA, UNITED STATES
Van Aken, Koen Jeanne Alfons, Turnhout, BELGIUM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083317	A1	20030501
APPLICATION INFO.:	US 2002-185528	A1	20020628 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-749181, filed on 27 Dec 2000, GRANTED, Pat. No. US 6440986 Continuation of Ser. No. US 1999-276360, filed on 25 Mar 1999, GRANTED, Pat. No. US 6197779

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1998-201587	19980514
	EP 1998-203948	19981125
	US 1998-79632P	19980327 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1

LINE COUNT: 1867

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns the use of the compounds of formula ##STR1##

the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR.sup.4 or N; n is 0 to 4; Q is hydrogen or --NR.sup.1R.sup.2; R.sup.1 and R.sup.2 are selected from hydrogen, hydroxy, C.sub.1-12alkyl, C.sub.1-12alkyloxy, C.sub.1-12alkylcarbonyl, C.sub.1-12alkyloxycarbonyl, aryl, amino, mono- or di(C.sub.1-12alkyl)-amino, mono- or di(C.sub.1-12alkyl)aminocarbonyl wherein each C.sub.1-12alkyl may optionally be substituted; or R.sup.1 and R.sup.2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C.sub.1-12alkyl)aminoC.sub.1-4alkylidene; R.sup.3 is hydrogen, aryl, C.sub.1-6alkylcarbonyl, optionally substituted C.sub.1-6alkyl, C.sub.16alkyloxy-carbonyl,; and R.sup.4 is hydroxy, halo, optionally substituted C.sub.1-6alkyl, C.sub.1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; R.sup.5 is hydrogen or C.sub.1-4alkyl; L is optionally substituted C.sub.1-10alkyl, C.sub.3-10alkenyl, C.sub.3-10alkynyl, C.sub.3-7cycloalkyl; or L is --X.sup.1--R.sup.6 or --X.sup.2--Alk--R.sup.7 wherein R.sup.6 and R.sup.7 are optionally substituted phenyl; X.sup.1 and X.sup.2 are --NR.sup.3--, --NH--NH--, --N.dbd.N--, --O--, --S--, --S(.dbd.O)-- or --S(.dbd.O).sub.2--; Alk is C.sub.1-4alkanediyl; aryl is potionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and

compositions comprising them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **244768-09-0P**
(prepn. of arylaminopyrimidines for treatment of human immunodeficiency virus infection)
RN 244768-09-0 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2,6-dichlorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 10 USPATFULL
ACCESSION NUMBER: 2002:75592 USPATFULL
TITLE: DNA glycosylase inhibitors, and uses related thereto
INVENTOR(S): Verdine, Gregory L., Lexington, MA, United States
Deng, Li, Brookline, MA, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6369237	B1	20020409
APPLICATION INFO.:	US 1997-812653		19970307 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Geist, Gary
ASSISTANT EXAMINER: Owens, Jr., Howard V.
LEGAL REPRESENTATIVE: Gordon, Dana M., Foley, Hoag & Eliot LLP
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2136
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention pertains to novel inhibitors of DNA glycosylases. The invention is based at least in part on the observation that specific substituted pyrrolidines, and analogs thereof, are capable of specifically inhibiting DNA glycosylases, e.g., as transition state analogs, and consequently are useful for modulation of DNA repair. Such compounds can, for example, be used for treating subjects having a disorder associated with excessive cell proliferation, such as in the treatment of various **cancers**. Furthermore, these glycosylase inhibitors can be used as anti-bacterial, anti-viral and anti-fungal agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **147-61-5DP**, nucleotide derivs. contg.
(DNA glycosylase inhibitors and their therapeutic uses)
RN 147-61-5 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 5-(hydroxymethyl)-6-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 10 USPATFULL

ACCESSION NUMBER:	2001:163203 USPATFULL
TITLE:	Uracil derivatives and antitumor effect potentiator and antitumor agent containing the same
INVENTOR(S):	Yano, Shingo, Kawagoe, Japan Tada, Yukio, Higashimatsuyama, Japan Kazuno, Hideki, Hanno, Japan Sato, Tsutomu, Hanno, Japan Yamashita, Junichi, Honjo, Japan Suzuki, Norihiko, Hidaka, Japan Emura, Tomohiro, Iruma, Japan Fukushima, Masakazu, Hanno, Japan Asao, Tetsuji, Tokorozawa, Japan
PATENT ASSIGNEE(S):	Taiho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6294535	B1	20010925
APPLICATION INFO.:	US 1999-457668		19991209 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-6009, filed on 12 Jan 1998, now patented, Pat. No. US 6159969 Division of Ser. No. US 737677, now patented, Pat. No. US 5744475

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-71667	19950329

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Shah, Mukund J.
ASSISTANT EXAMINER:	Truong, Tamthom N.
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS:	15
EXEMPLARY CLAIM:	1
LINE COUNT:	2156

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel uracil derivatives having excellent inhibiting effects on human derived thymidine phosphorylates and anti-**tumor** activity. The pharmaceutical compositions, anti-**tumor** potentiators and antitumor agents containing such novel compounds, and a process for their preparation and use are described. The novel uracil derivative compounds are represented by the general formula (1'): ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **183204-36-6P 183204-37-7P 183204-79-7P 183204-81-1P 183205-13-2P 183205-14-3P**
(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)

RN 183204-36-6 USPATFULL

CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-2,4-dioxo-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-37-7 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-79-7 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2-imino-1-pyrrolidinyl)methyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183204-81-1 USPATFULL
CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 183205-13-2 USPATFULL
CN Carbamimidothioic acid, (1,2,3,6-tetrahydro-5-methyl-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183205-14-3 USPATFULL
CN Carbamimidothioic acid, (5-cyano-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **183205-45-0P**
(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)
RN 183205-45-0 USPATFULL
CN 5-Pyrimidinecarbonitrile, 6-(chloromethyl)-1,2,3,4-tetrahydro-2,4-dioxo- (9CI) (CA INDEX NAME)



L7 ANSWER 6 OF 10 USPATFULL
ACCESSION NUMBER: 2001:123586 USPATFULL
TITLE: HIV inhibiting pyrimidine derivatives
INVENTOR(S): Andries, Koenraad Jozef Lodewijk Marcel, Beerse, Belgium
De Corte, Bart, Southampton, PA, United States
De Jonge, Marc Rene, CA Tilburg, Netherlands
Heeres, Jan, Vosselaar, Belgium
Ho, Chih Yung, Lansdale, PA, United States
Janssen, Marcel August Constant, Vosselaar, Belgium
Janssen, Paul Adriaan Jan, Vosselaar, Belgium
Koymans, Lucien Maria Henricus, Turnhout, Belgium

Kukla, Michael Joseph, Maple Glen, PA, United States
Ludovici, Donald William, Quakertown, PA, United States
Van Aken, Koen Jeanne Alfons, Turnhout, Belgium

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011094	A1	20010802
	US 6440986	B2	20020827
APPLICATION INFO.:	US 2000-749181	A1	20001227 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-276360, filed on 25 Mar 1999, GRANTED, Pat. No. US 6197779

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1998-201587	19980514
	EP 1998-203948	19981125
	US 1998-79632P	19980327 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Philip S. Johnson, Esq., Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ, 08933-7003
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 1898

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns the use of the compounds of formula ##STR1##

the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR.sup.4 or N; n is 0 to 4; Q is hydrogen or --NR.sup.1R.sup.2; R.sup.1 and R.sup.2 are selected from hydrogen, hydroxy, C.sub.1-12alkyl, C.sub.1-12alkyloxy, C.sub.1-12alkylcarbonyl, C.sub.1-12alkyloxycarbonyl, aryl, amino, mono- or di(C.sub.1-12alkyl)amino, mono- or di(C.sub.1-12alkyl)aminocarbonyl wherein each C.sub.1-12alkyl may optionally be substituted; or R.sup.1 and R.sup.2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C.sub.1-12alkyl)aminoC.sub.1-4alkylidene; R.sup.3 is hydrogen, aryl, C.sub.1-6alkylcarbonyl, optionally substituted C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl,; and R.sup.4 is hydroxy, halo, optionally substituted C.sub.1-6alkyl, C.sub.1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; R.sup.5 is hydrogen or C.sub.1-4alkyl; L is optionally substituted C.sub.1-10alkyl, C.sub.3-10alkenyl, C.sub.3-10alkynyl, C.sub.3-7cycloalkyl; or L is --X.sup.1--R.sup.6 or --X.sup.2--Alk--R.sup.7 wherein R.sup.6 and R.sup.7 are optionally substituted phenyl; X.sup.1 and X.sup.2 are --NR.sup.3--, --NH--NH--, --N.dbd.N--, --O--, --S--, --S(.dbd.O)-- or --S(.dbd.O).sub.2--; Alk is C.sub.1-4alkanediyl; aryl is potionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical: for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **244768-09-0P**
(prepn. of arylaminopyrimidines for treatment of human immunodeficiency virus infection)

RN 244768-09-0 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2,6-dichlorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 7 OF 10 USPATFULL

ACCESSION NUMBER:	2001:102824 USPATFULL			
TITLE:	Cancerous metastasis inhibitors containing uracil derivatives			
INVENTOR(S):	Miyadera, Kazutaka, Hanno, Japan Emura, Tomohiro, Iruma, Japan Wierzba, Konstanty, Sayama, Japan Yamada, Yuji, Higashiyamato, Japan			
PATENT ASSIGNEE(S):	Taiho Charmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6255314	B1	20010703	
	WO 9813045		19980402	
APPLICATION INFO.:	US 1998-77209		19980526	(9)
	WO 1997-JP3355		19970922	
			19980526	PCT 371 date
			19980526	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	JP 1996-251303		19960924	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Raymond, Richard L.			
ASSISTANT EXAMINER:	Balasubramanian, Venkataraman			
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas, PLLC			
NUMBER OF CLAIMS:	7			
EXEMPLARY CLAIM:	1			
LINE COUNT:	2020			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a drug which has inhibitory activities against thymidine phosphorylase and inhibits metastasis of a **cancer**. Specifically, this invention relates to a cancerous metastasis inhibitor comprising, as an active ingredient, a uracil derivative represented by the following formula (1): ##STR1##

wherein R.sup.1 represents a chlorine, bromine or iodine atom or a cyano or lower alkyl group and R.sup.2 represents a substituted or unsubstituted 4-8 membered hetero-cyclic group having nitrogen atoms or a substituted or unsubstituted amidinothio, guanidino, (lower alkyl)amidino, amino or like group, or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **183204-36-6P 183204-37-7P 183204-79-7P 183204-81-1P 183205-13-2P 183205-14-3P**
(prepn. of uracil derivs. as cancer metastasis inhibitors)

RN 183204-36-6 USPATFULL

CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-2,4-dioxo-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-37-7 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-79-7 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2-imino-1-pyrrolidinyl)methyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183204-81-1 USPATFULL
CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 183205-13-2 USPATFULL
CN Carbamimidothioic acid, (1,2,3,6-tetrahydro-5-methyl-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183205-14-3 USPATFULL
CN Carbamimidothioic acid, (5-cyano-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **183205-45-0P**
(prepn. of uracil derivs. as cancer metastasis inhibitors)
RN 183205-45-0 USPATFULL
CN 5-Pyrimidinecarbonitrile, 6-(chloromethyl)-1,2,3,4-tetrahydro-2,4-dioxo- (9CI) (CA INDEX NAME)



L7 ANSWER 8 OF 10 USPATFULL
ACCESSION NUMBER: 2001:33276 USPATFULL
TITLE: HIV inhibiting pyrimidine derivative
INVENTOR(S): Andries, Koenraad Jozef Lodewijk Marcel, Beerse, Belgium
De Corte, Bart, Southampton, PA, United States
De Jonge, Marc Rene, Tilburg, Netherlands
Heeres, Jan, Vosselaar, Belgium
Ho, Chih Yung, Lansdale, PA, United States
Janssen, Marcel August Constant, Vosselaar, Belgium
Janssen, Paul Adriaan Jan, Vosselaar, Belgium
Koymans, Lucien Maria Henricus, Turnhout, Belgium
Kukla, Michael Joseph, Maple Glen, PA, United States

	Ludovici, Donald William, Quakertown, PA, United States Van Aken, Koen Jeanne Alfons, Turnhout, Belgium
PATENT ASSIGNEE(S):	Janssen Pharmaceutica, Inc., New Brunswick, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6197779	B1	20010306	
APPLICATION INFO.:	US 1999-276360		19990325	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	EP 1998-201587	19980514	
	EP 1998-203948	19981125	
	US 1998-79632P	19980327	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Shah, Mukund J.
ASSISTANT EXAMINER:	Liu, Hong
LEGAL REPRESENTATIVE:	Appollina, Mary
NUMBER OF CLAIMS:	4
EXEMPLARY CLAIM:	1
LINE COUNT:	1660

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns the use of the compounds of formula ##STR1##

the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR.sup.4 or N; n is 0 to 4; Q is hydrogen or --NR.sup.1 R.sup.2 ; R.sup.1 and R.sup.2 are selected from hydrogen, hydroxy, C.sub.1-12 alkyl, C.sub.1-12 alkyloxy, C.sub.1-12 alkylcarbonyl, C.sub.1-12 alkyloxycarbonyl, aryl, amino, mono- or di(C.sub.1-12 alkyl)amino, mono- or di(C.sub.1-12 alkyl)aminocarbonyl wherein each C.sub.1-12 alkyl may optionally be substituted; or R.sup.1 and R.sup.2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C.sub.1-12 alkyl)aminoC.sub.1-4 alkylidene; R.sup.3 is hydrogen, aryl, C.sub.1-6 alkylcarbonyl, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 alkyloxycarbonyl,; and R.sup.4 is hydroxy, halo, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; R.sup.5 is hydrogen or C.sub.1-4 alkyl; L is optionally substituted C.sub.1-10 alkyl, C.sub.3-10 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl; or L is --X.sup.1 --R.sup.6 or --X.sup.2 -Alk-R.sup.7 wherein R.sup.6 and R.sup.7 are optionally substituted phenyl; X.sup.1 and X.sup.2 are --NR.sup.3 --, --NH--NH--, --N.dbd.N--, --O--, --S--, --S(.dbd.O)-- or --S(.dbd.O).sub.2 --; Alk is C.sub.1-4 alkanediyl; aryl is potionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **244768-09-0P**
(prepn. of arylaminopyrimidines for treatment of human immunodeficiency virus infection)

RN 244768-09-0 USPATFULL

CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2,6-dichlorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 9 OF 10 USPATFULL

ACCESSION NUMBER:	2000:168016 USPATFULL
TITLE:	Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
INVENTOR(S):	Yano, Shingo, Kawagoe, Japan Tada, Yukio, Higashimatsuyama, Japan Kazuno, Hideki, Hanno, Japan Sato, Tsutomu, Hanno, Japan Yamashita, Junichi, Honjo, Japan Suzuki, Norihiko, Hidaka, Japan Emura, Tomohiro, Iruma, Japan Fukushima, Masakazu, Hanno, Japan Asao, Tetsuji, Tokorozawa, Japan
PATENT ASSIGNEE(S):	Taiho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6159969		20001212
APPLICATION INFO.:	US 1998-6009		19980112 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-737677, filed on 21 Nov 1996, now patented, Pat. No. US 5744475		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-71667	19950329

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Shah, Mukund J.
ASSISTANT EXAMINER:	Truong, Tamthom N.
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS:	14
EXEMPLARY CLAIM:	1
LINE COUNT:	2555

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel uracil derivatives having excellent inhibiting effects of human derived thymidine phosphorylase and anti-**tumor** activity. The pharmaceutical compositions, anti-**tumor** potentiators, antitumor agents containing such novel compounds, and a process for their preparation and use is described. The novel compounds satisfy the general formula (1): ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **183204-36-6P 183204-37-7P 183204-79-7P 183204-81-1P 183205-13-2P 183205-14-3P**
(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)

RN 183204-36-6 USPATFULL

CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-2,4-dioxo-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-37-7 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-79-7 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2-imino-1-pyrrolidinyl)methyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183204-81-1 USPATFULL
CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 183205-13-2 USPATFULL
CN Carbamimidothioic acid, (1,2,3,6-tetrahydro-5-methyl-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183205-14-3 USPATFULL
CN Carbamimidothioic acid, (5-cyano-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **183205-45-0P**
(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)
RN 183205-45-0 USPATFULL
CN 5-Pyrimidinecarbonitrile, 6-(chloromethyl)-1,2,3,4-tetrahydro-2,4-dioxo- (9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 10 USPATFULL
ACCESSION NUMBER: 1998:45210 USPATFULL
TITLE: Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
INVENTOR(S): Yano, Shingo, Kawagoe, Japan
Tada, Yukio, Higashimatsuyama, Japan
Kazuno, Hideki, Hanno, Japan
Sato, Tsutomu, Hanno, Japan
Yamashita, Junichi, Honjo, Japan
Suzuki, Norihiko, Hidaka, Japan
Emura, Tomohiro, Iruma, Japan
Fukushima, Masakazu, Hanno, Japan

	Asao, Tetsuji, Tokorozawa, Japan			
PATENT ASSIGNEE(S):	Taiho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5744475		19980428	
	WO 9630346		19961003	
APPLICATION INFO.:	US 1996-737677		19961121	(8)
	WO 1996-JP828		19960328	
			19961121	PCT 371 date
			19961121	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-71667	19950329

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Ngo, Tamthom T.
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 2388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel uracil derivatives having excellent inhibiting effects of human derived thymidine phosphorylase and anti-**tumor** activity. The pharmaceutical compositions, anti-**tumor** potentiators, antitumor agents containing such novel compounds, and a process for their preparation and use is described. The novel compounds satisfy the general formula (1): ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **183204-36-6P 183204-37-7P 183204-79-7P**
183204-81-1P 183205-13-2P 183205-14-3P
(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)
RN 183204-36-6 USPATFULL
CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-2,4-dioxo-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-37-7 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl-6-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 183204-79-7 USPATFULL
CN 2,4(1H,3H)-Pyrimidinedione, 6-[(2-imino-1-pyrrolidinyl)methyl]-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183204-81-1 USPATFULL
CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 183205-13-2 USPATFULL
CN Carbamimidothioic acid, (1,2,3,6-tetrahydro-5-methyl-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183205-14-3 USPATFULL

CN Carbamimidothioic acid, (5-cyano-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **183205-45-0P**
(prepn. of uracil derivs. as antitumor activity potentiators and antitumor agents)
RN 183205-45-0 USPATFULL
CN 5-Pyrimidinecarbonitrile, 6-(chloromethyl)-1,2,3,4-tetrahydro-2,4-dioxo- (9CI) (CA INDEX NAME)



=>